<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03452462</url>
  </required_header>
  <id_info>
    <org_study_id>HisCRT_GVA</org_study_id>
    <nct_id>NCT03452462</nct_id>
  </id_info>
  <brief_title>Electrical Resynchronization and Acute Hemodynamic Effects of Direct His Bundle Pacing Compared to Biventricular Pacing</brief_title>
  <official_title>Electrical Resynchronization and Acute Hemodynamic Effects of Direct His Bundle Pacing Compared to Biventricular Pacing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Fund for Scientific Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims are to compare Direct His Bundle Pacing (DHBP) with biventricular pacing (BiV) in&#xD;
      terms of electrical resynchronization using electrocardiographic imaging (ECGI) and also in&#xD;
      terms of acute hemodynamical effect using finger plethysmography and conduction velocimetry.&#xD;
      The study will be a randomized crossover design with acute measurements.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By recruiting native conducting tissue to relay electrical activation of the ventricles via&#xD;
      the Purkinje fibre network, DHBP may potentially achieve greater electrical resynchronization&#xD;
      and hemodynamic benefit compared to BiV where the electrical activation wavefronts propagate&#xD;
      from two discrete pacing sites. Electrical synchrony achieved by these pacing modes have&#xD;
      however never been compared. Furthermore, the acute hemodynamic effect of DHBP has been&#xD;
      compared to BiV only in a small single study to date. The aims are to compare DHBP with BiV&#xD;
      in terms of electrical resynchronization using electrocardiographic imaging (ECGI) and also&#xD;
      in terms of acute hemodynamical effect using finger plethysmography and conduction&#xD;
      velocimetry. The primary endpoint will be left ventricular activation time, with secondary&#xD;
      endpoints including various electrical (right ventricular activation time, total ventricular&#xD;
      activation time etc) and hemodynamic parameters (systolic pressure, cardiac output, cardiac&#xD;
      contractility). It is expected that DHBP offers shorter left ventricular activation time&#xD;
      (i.e. better synchrony) and hemodynamic benefit compared to BiV.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Actual">November 26, 2020</completion_date>
  <primary_completion_date type="Actual">August 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular activation time</measure>
    <time_frame>5 minutes</time_frame>
    <description>Duration of left ventricular electrical activation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Right ventricular activation time</measure>
    <time_frame>5 minutes</time_frame>
    <description>Duration of right ventricular electrical activation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total ventricular activation time</measure>
    <time_frame>5 minutes</time_frame>
    <description>Duration of total ventricular electrical activation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic pressure</measure>
    <time_frame>5 minutes</time_frame>
    <description>Systolic blood pressure measured by finger plethysmography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>5 minutes</time_frame>
    <description>Cardiac output measured by conductive velocimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac contractility</measure>
    <time_frame>5 minutes</time_frame>
    <description>Cardiac contractilit measured by conductive velocimetry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Cardiac Pacing, Artificial</condition>
  <condition>Cardiac Resynchronization Therapy</condition>
  <condition>Direct His Bundle Pacing</condition>
  <arm_group>
    <arm_group_label>Direct His Bundle Pacing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pacing from the His bundle lead</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biventricular Pacing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pacing from the right ventricular and coronary sinus leads</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pacing</intervention_name>
    <description>Programming of either Direct His Bundle pacing or biventricular pacing</description>
    <arm_group_label>Biventricular Pacing</arm_group_label>
    <arm_group_label>Direct His Bundle Pacing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Treatment of heart failure with a standard indication for CRT (NYHA III-IV, LVEF &lt; 35%&#xD;
             and QRS &gt; 130ms; or LVEF&lt; 40% and requirement for frequent ventricular pacing,&#xD;
             irrespective of baseline QRS duration) and optimal medical treatment.&#xD;
&#xD;
               -  Permanent atrial fibrillation (allowing connection of the DHBP lead to the atrial&#xD;
                  port).&#xD;
&#xD;
               -  Patients implanted with 1) a CRT pacemaker or CRT defibrillator 2) a His lead&#xD;
                  with selective or non-selective DHBP, connected to the atrial port of the&#xD;
                  generator 3) a functional right ventricular lead and 4) a functional coronary&#xD;
                  sinus lead.&#xD;
&#xD;
               -  DHBP with selective or non-selective His capture&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Inability to undergo CT or an MRI (e.g. due to severe claustrophobia)&#xD;
&#xD;
          -  Inability or refusal to sign the patient informed consent form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Geneva</name>
      <address>
        <city>Geneva</city>
        <state>GE</state>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 25, 2018</study_first_submitted>
  <study_first_submitted_qc>February 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <last_update_submitted>November 28, 2020</last_update_submitted>
  <last_update_submitted_qc>November 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Haran Burri, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

